The demand for fully human therapeutic antibodies continues to grow, driving the need for more efficient discovery platforms. Traditional methods, such as hybridoma technology, can be time-intensive and limited in diversity. In response, Biointron has developed AbDrop™, a microfluidic, droplet-based single B cell screening platform designed to accelerate and enhance antibody discovery.
Unlike conventional approaches, AbDrop™ directly screens naturally matured individual B cells, maximizing CDR diversity by mining the entire plasma cell repertoire. This high-throughput system enables rapid identification of natively paired sequences, significantly reducing the discovery timeline to just 2–3 months.
This white paper outlines how AbDrop™ streamlines antibody discovery, providing an efficient, scalable, and precise solution for biopharmaceutical innovation.